Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Mavenclad

Shire Basingstoke

Shire gives up on Momenta-partnered Humira biosimilar

Will fund programme for another 12 months while divesting ongoing activities to Momenta

- PMLiVE

Novartis seeks first-line use for lung cancer drug Zykadia

Looks to go head-to-head with Pfizer/Merck KGaA’s Xalkori and Roche’s Alecensa

Novartis day

Novartis drug works in secondary progressive MS

Orally-active siponimod reduces risk of disability progression

- PMLiVE

EMD Serono president James Hoyes joins consultants RxC

Takes up a role as executive partner at the US management consulting firm

- PMLiVE

Fertility drugs drive healthcare growth at Merck KGaA

Strong performances from Gonal-f and Rebif boost the firm’s 2016 sales forecast

Biogen Idec building

Biogen’s CEO Scangos to step down

Departure comes as multiple sclerosis drug Tecfidera achieves improved sales growth

Novartis Gehry Building

New drugs help Novartis shrug off Gleevec competition

However, warns of lesser profits this year as firm looks to boost promotion of Entresto

Roche Basel Switzerland

Roche’s MS drug Ocrevus awarded priority review by FDA

Comes as Swiss company files the therapy with the FDA and EMA

Merck’s accelerator to take start-ups to Silicon Valley

Will expand the reach of its Darmstadt and Nairobi programmes

Biogen Idec building

Biogen multiple sclerosis drug flunks clinical trial

Opicinumab had been proposed as a possible reparative therapy in MS

- PMLiVE

Sanofi Genzyme launches multiple sclerosis awareness campaign

Aims to highlight and address the physical and emotional burden of the disease

Biogen Idec building

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Once-monthly, self-administered Zinbryta ‘significantly’ reduces relapse rate

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links